Immunostimulatory Conjugates for Tumor-Specific Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack tumor specificity, leading to adverse side effects and inadequate clinical responses, as they fail to effectively boost the immune response against cancer cells without harming normal cells, and cancer vaccines face limitations due to immune evasion strategies employed by tumors.
Innovation Solution
The development of immunostimulatory compositions and methods involving conjugates of immune co-stimulatory polypeptides and antigens, using binding pairs like avidin and biotin, to enhance the immune response by facilitating antigen presentation and activating immune cells, such as T cells and dendritic cells, to target tumor-associated antigens or infectious agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer therapies (surgery, chemotherapy, radiotherapy) are used, then treatment can be provided, but tumor specificity is lacking resulting in adverse side effects and less than satisfactory clinical responses
Solution Approach 1:
The invention segments the immune response into distinct functional components: antigen presentation (Signal 1 via MHC-TCR interaction), costimulation (Signal 2 via molecules like B7-1/B7-2 and their receptors), and cytokine signaling (Signal 3). By separately optimizing each signal component through engineered cell compositions, the therapy achieves tumor-specific efficacy while minimizing off-target effects on normal cells.
Solution Approach 2:
The invention uses engineered immune cells (dendritic cells, T cells, NK cells) as intermediaries that bridge the gap between tumor antigens and the immune system. These cells are modified to express specific receptors, costimulatory molecules, and cytokines that enhance antigen recognition and immune activation specifically at tumor sites, thereby improving clinical response while reducing systemic toxicity.
2Reliability
If immune response is boosted to target cancer cells, then tumor eradication may be achieved, but normal cells may be harmed
Solution Approach 1:
The invention imparts local quality to the immune response by engineering cells to express tumor-specific receptors and costimulatory molecules that are activated preferentially at tumor sites. The modified dendritic cells and T cells display enhanced antigen-presenting capacity and costimulatory activity specifically where tumor antigens are present, enabling selective tumor eradication while sparing normal cells from immune-mediated damage.
3Object-affected harmful factors
If cancer vaccines are used, then tumor specificity is improved, but efficacy is limited due to immune evasion strategies employed by tumors
Solution Approach 1:
The invention merges multiple immune activation mechanisms into a single therapeutic composition: antigen presentation by dendritic cells, costimulatory signaling through engineered receptor-ligand pairs (e.g., B7-1/CD28, B7-2/CTLA-4), and cytokine enhancement. This combination overcomes tumor immune evasion strategies by simultaneously providing all three signals required for robust T cell activation, thereby maintaining tumor specificity while significantly improving vaccine efficacy.
Solution Approach 2:
The invention creates composite immune cell compositions that integrate multiple functional elements: dendritic cells engineered to express specific costimulatory molecules, T cells modified with enhanced receptor expression, and NK cells with improved cytotoxic activity. These composite cellular compositions work synergistically to overcome tumor immune evasion while maintaining specificity for tumor-associated antigens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the immune response against tumors or infectious agents, potentially reducing tumor size and inhibiting their growth by specifically activating immune cells to recognize and attack cancer cells or infected cells, while minimizing harm to normal cells.
Implementation Method 1
conjugates of immune co-stimulatory polypeptides and antigens, using binding pairs like avidin and biotin
Data Source
AI summary
The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections.